Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis Tislelizumab Meets Primary Endpoint of Overall Survival in Esophageal Cancer

americanpharmaceuticalreviewJune 08, 2021

Tag: Novartis , Tislelizumab , ESCC , RATIONALE 302

PharmaSources Customer Service